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Proximal spinal muscular atrophy (SMA), a leading genetic cause of infant
death worldwide, is an early-onset, autosomal recessive neurodegenerative disease
characterized by the loss of spinal α-motor neurons. This loss of α-motor neurons is
associated with muscle weakness and atrophy. SMA can be classified into five clinical
grades based on age of onset and severity of the disease. Regardless of clinical grade,
proximal SMA results from the loss or mutation of SMN1 (survival motor neuron 1) on
chromosome 5q13. In humans a large tandem chromosomal duplication has lead to a
second copy of the SMN gene locus known as SMN2. SMN2 is distinguishable from
SMN1 by a single nucleotide difference that disrupts an exonic splice enhancer in exon
7. As a result, most of SMN2 mRNAs lack exon 7 (SMN17) and produce a protein that
is both unstable and less than fully functional. Although only 10–20% of the SMN2 gene
product is fully functional, increased genomic copies of SMN2 inversely correlates with
disease severity among individuals with SMA. Because SMN2 copy number influences
disease severity in SMA, there is prognostic value in accurate measurement of SMN2
copy number from patients being evaluated for SMA. This prognostic value is especially
important given that SMN2 copy number is now being used as an inclusion criterion for
SMA clinical trials. In addition to SMA, copy number variations (CNVs) in the SMN genes
can affect the clinical severity of other neurological disorders including amyotrophic lateral
sclerosis (ALS) and progressive muscular atrophy (PMA). This review will discuss how
SMN1 and SMN2 CNVs are detected and why accurate measurement of SMN1 and
SMN2 copy numbers is relevant for SMA and other neurodegenerative diseases.
Keywords: spinal muscular atrophy, amyotrophic lateral sclerosis, progressive muscular atrophy,
neurodegenerative disease, copy number variation, SMN1, SMN2
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INTRODUCTION
Proximal spinal muscular atrophy (SMA) is a leading genetic
cause of infant death worldwide, alongside cystic fibrosis. The
incidence of SMA is 1 in 6000–10,000 live births (Pearn, 1978;
Cuscó et al., 2002; Sugarman et al., 2012). The carrier frequency
for SMA is 1:25–50 in most populations (Ben-Shachar et al.,
2011; Su et al., 2011; Lyahyai et al., 2012; Sugarman et al., 2012)
though it is lower for some ethnicities (Zaldívar et al., 2005;
Labrum et al., 2007; Hendrickson et al., 2009; Sangaré et al.,
2014).
SMA is an early-onset neurodegenerative disease
characterized by the loss of α-motor neurons in the anterior
horn of the spinal cord, i.e., lower motor neurons (LMNs;
Crawford and Pardo, 1996; Kolb and Kissel, 2015). This loss
of α-motor neurons is associated with muscle weakness and
atrophy. In SMA, those muscles that are proximally innervated
are preferentially affected over distal muscles. SMA can be
classified into five clinical grades based on age of onset and
severity of the disease (Munsat and Davies, 1992; Russman,
2007; Table 1). Type 0 SMA infants present with very severe
hypotonia and require respiratory support from birth. These
SMA infants cannot survive beyond 6 months. Type I SMA
[listed in the Online Inheritance in Man (OMIM) database
under accession number 253300; http://www.omim.org/entry/
253300] patients have an age of onset before 6 months. They
show hypotonia and weakness in limbs; they are unable to sit
independently. Type I SMA infants show a bell-shaped chest
due to weakness in the intercostals muscles but sparing of the
diaphragm; this bell-shaped chest results in abnormal breathing
patterns. These patients typically live <2 years. Type II SMA
(http://www.omim.org/entry/253500) patients have an age of
onset before 18 months. They are poor crawlers and weak sitters;
most of these patients can rarely stand and only with support.
Their legs are generally weaker than their arms. Due in part
to better supportive care, these patients generally have a life
expectancy into early adulthood. Type III SMA (http://www.
omim.org/entry/253400) patients have an age of onset >18
months. These patients are able to walk with difficulty (waddling
gait) and the legs are weaker than the arms. Type III patients
usually have a normal lifespan. Adult-onset (type IV) SMA
(http://www.omim.org/entry/271150) patients have an age
of onset of 18–21 years. Type IV SMA exhibits as a slowly
progressive limb weakness. The disease is fairly benign in these
patients.
Abbreviations: ALS, amyotrophic lateral sclerosis; CNV, copy number
variation; dPCR, digital polymerase chain reaction; FUS, fused in sarcoma;
GTF2H2, general transcription factor IIH; LMN, lower motor neuron; MLPA,
multiple ligation-dependent probe amplification; NAIP, neuronal apoptosis
inhibitory protein; OMIM, Online Mendelian Inheritance in Man; PCR-
RFLP, polymerase chain reaction-restriction fragment length polymorphism;
PMA, progressive muscular atrophy; SERF1A, small EDRK-rich factor 1A;
SMA, spinal muscular atrophy; SMN17, survival motor neuron lacking
exon 7; SMN1, survival motor neuron 1; SMN2, survival motor neuron
2; snRNP, small nuclear ribonucleoprotein particle; SOD1, superoxide
dismutase 1; TDP-43, TAR DNA binding protein-43kDa; UMN, upper motor
neuron.
GENETICS OF SMA
SMA is an autosomal recessive disorder (Brandt, 1949). Linkage
analysis (Brzustowicz et al., 1990; Gilliam et al., 1990; Melki
et al., 1990a,b) along with genetic and physical mapping studies
(reviewed in Morrison, 1996) identified the SMA locus on the
long arm of chromosome 5, specifically in the 5q13 region. There
is a 500 kilobase (kb) inverted segmental duplication within this
region of chromosome 5 that is unique to humans (Courseaux
et al., 2003; Schmutz et al., 2004). Four protein-coding genes have
been identified within this region (Figure 1): SMN1 [survival
motor neuron 1, telomeric SMN (SMNT ; Lefebvre et al., 1995)],
NAIP [neuronal apoptosis inhibitor protein (Roy et al., 1995)],
GTF2H2A [general transcription factor IIH, p44 (Bürglen et al.,
1997; Carter et al., 1997)], and SERF1A [small EDRK-rich factor
1A, H4F5A (Scharf et al., 1998)]. The duplicated genes are either
identical to their partner gene (SERF1B), different in a small
number of nucleotides [SMN2 or centromeric SMN (SMNC)] or
are pseudogenes (ΨGTF2H2B and ΨNAIP15).
In more than 95% of cases, proximal SMA results from the
loss of SMN1 but retention of SMN2, regardless of clinical grade
(Lefebvre et al., 1995). Large-scale deletions in chromosome 5q13
that include SMN1, NAIP, SERF1A, and GTF2H2A are observed
in patients with type I SMA (Wirth et al., 1995; Burlet et al., 1996;
Rodrigues et al., 1996; Velasco et al., 1996; Bürglen et al., 1997;
Carter et al., 1997). Smaller deletions only involving SMN1 have
also been observed in type I SMA patients demonstrating that
SMN1 is the most likely causative gene for SMA. In addition, the
identification of intragenic SMA mutations in SMN1 (Lefebvre
et al., 1995; see Burghes and Beattie, 2009 for a comprehensive
listing of SMA-associated point mutations in SMN1) provides
additional evidence to support SMN1 as the gene responsible for
SMA. To date, no intragenic mutations in the other genes within
this segmental duplication have been associated with SMA.
As mentioned earlier, the SMN gene is duplicated in humans
to give rise to SMN1 and SMN2. This duplication of SMN
is unique to humans (Rochette et al., 2001). What is the
difference between SMN1 and SMN2? The major difference
between these two SMN genes is a C-to-T transition in exon
7(SMN2 c.850C>T; Lorson et al., 1999; Monani et al., 1999).
This nucleotide change is translationally silent. This position
on exon 7 is in the middle of an exonic splicing enhancer
(ESS) sequence that regulated the inclusion of exon 7 in
SMN transcripts (Figure 2). For SMN1, the C at this position
promotes inclusion of exon 7 in SMN1-derived mRNAs which
leads to the production of full-length SMN protein. Full-length
SMN protein is able to form functional complexes. For SMN2,
the T at this position disrupts this ESS which results in the
exclusion of exon 7 (SMN17) from the majority of SMN2-
derived mRNAs. As a result, a truncated SMN17 protein is
produced by the majority (∼90%) of SMN2-derived mRNAs;
this SMN17 protein is unstable and is unable to associate with
itself (Lorson and Androphy, 2000; Burnett et al., 2009; Cho and
Dreyfuss, 2010). The SMN17 protein is still partially functional
given that transgenic overexpression of SMN17 in severe SMA
mice partially ameliorates their phenotype since these mice die
at 14–15 days as opposed to 5–8 days (Le et al., 2005). About
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TABLE 1 | Clinical classification of spinal muscular atrophy (SMA).
Type Age of onset Requires respiratory
support at birth
Able to sit Able to stand Able to walk Life expectancy Predicted SMN2
copy number
0 Prenatal Yes No No No <6 months 1
1 <6 months No No No No <2 years 2
2 6–18 months No Yes No No 10–40 years 3
3 >18 months No Yes Yes Assisted Adult 3–4
4 >5 years No Yes Yes Yes Adult >4
FIGURE 1 | Organization of the inverted duplication locus on 5q13. 4 protein-coding genes—GTF2H2 (general transcription factor IIH), NAIP (neuronal
apoptosis inhibitory protein), SMN1 (survival motor neuron 1), and SERF1A (small EDRK-rich factor 1A)—are present within the 500-kilobase inverted duplication on
the long arm of chromosome 5 (5q13.2). The duplicated genes are ΨGTF2H2B (GTF2H2 pseudogene), ΨNAIP15 (NAIP pseudogene with loss of exon 5), SMN2,
and SERF1B. The SMA critical region is under the gray bar. C, centromeric end; T, telomeric end.
10% of the mRNAs from SMN2 contain exon 7 and these full-
length mRNAs can produce some full-length, functional SMN
protein.
BIOLOGY OF SMN
SMN is a ubiquitously expressed protein whose expression is
reduced in SMA. There is a strong inverse correlation between
SMN protein levels and disease severity in SMA fibroblasts and
lymphoblastoid cells as well (Coovert et al., 1997; Lefebvre et al.,
1997; Kolb et al., 2006). Changes in SMN mRNA and protein
levels observed in SMA patient-derived PBMCs mirror those
observed in SMA cell lines (Sumner et al., 2006; Simard et al.,
2007; Vezain et al., 2007; Tiziano et al., 2010; Crawford et al.,
2012). SMN protein is present within the nuclei in discreet foci
known as gems (Liu and Dreyfuss, 1996). In SMA fibroblasts,
the number of SMN-positive subnuclear gems is higher in cells
derived from mild SMA individuals than in those from children
with more severe forms of SMA (Coovert et al., 1997).
SMN is required for the assembly of the small nuclear
ribonucleoprotein (snRNP) complexes that mediate splicing
(Pellizzoni, 2007; Burghes and Beattie, 2009). snRNP assembly
is defective in SMN-deficient SMA cells (Wan et al., 2005).
Since snRNP assembly is required for all cell types, why are
motor neurons primarily affected in SMA? snRNP assembly is
defective in tissues from mouse models for SMA and that the
extent of reduced snRNP assembly correlates with phenotypic
severity of these SMA mice (Gabanella et al., 2005; Zhang et al.,
2008). snRNP assembly is moremarkedly reduced in SMAmouse
neural tissues than in other tissues like the kidney (Gabanella
et al., 2005) suggesting that motor neurons are more sensitive
to deficits in snRNP assembly. SMN may also have a function
that is unique to motor neurons. Axonal defects in Smn-knocked
down zebrafish embryos (McWhorter et al., 2003) are corrected
by overexpression ofmutant SMNswhich are incapable of snRNP
assembly (Carrel et al., 2006).
SMN2 CNV IN SMA
The number of SMN2 copies in the genome varies between 0 and
8. Numerous studies have demonstrated an inverse relationship
between SMN2 copy number and disease severity among in SMA
(Lefebvre et al., 1995, 1997; van der Steege et al., 1995; Coovert
et al., 1997; McAndrew et al., 1997; Taylor et al., 1998; Feldkötter
et al., 2002; Mailman et al., 2002; Anhuf et al., 2003; Gérard et al.,
2004; Prior et al., 2005; Su et al., 2005; Swoboda et al., 2005;
Arkblad et al., 2006; Scarciolla et al., 2006; Wirth et al., 2006;
Gómez-Curet et al., 2007; Huang et al., 2007; Tiziano et al., 2007;
Elsheikh et al., 2009;Wang et al., 2010a,b, 2014a; Alías et al., 2011;
Amara et al., 2012; Crawford et al., 2012; Dobrowolski et al., 2012;
Kirwin et al., 2013; Qu et al., 2014; Brkušanin et al., 2015; Fang
et al., 2015; Stabley et al., 2015). Patients with milder forms of
SMA have higher SMN2 copy numbers than severe SMA patients
(Table 1).
Mice have only 1 SMN gene, mSmn, which is orthologous to
SMN1 (DiDonato et al., 1997a; Viollet et al., 1997). Loss ofmSmn
leads to embryonic lethality (Schrank et al., 1997). Conditional
loss of mSmn in specific cell types like neurons, myofibers and
hepatocytes results in loss of those cells in vivo (Cifuentes-Diaz
et al., 2002; Nicole et al., 2003; Vitte et al., 2004). Transgenic
insertion of SMN2 rescues the embryonic lethality observed in
mSmn nullizygous mice (Hsieh-Li et al., 2000; Monani et al.,
2000; Michaud et al., 2010). While two copies of SMN2 rescues
embryonic lethality in mSmn-deficient mice, these mice develop
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FIGURE 2 | The effect of the C-to-T transition in exon 7 between SMN1 and SMN2 on splicing. Adapted from Butchbach and Burghes (2004).
a very severe motor phenotype and die within 8 days after birth
(Hsieh-Li et al., 2000;Monani et al., 2000). ThosemSmn-deficient
mice with 3-4 SMN2 copies exhibit a milder SMA phenotype than
the two copy SMN2 SMA mice (Hsieh-Li et al., 2000; Michaud
et al., 2010). If the SMN2 copy number is high (i.e., 8), then
the resultant mSmn-deficient mice exhibit no signs of SMA and
are phenotypically normal (Monani et al., 2000). SMN2 CNV,
therefore, is a major modifier of disease severity in SMA in mice
as well as in humans.
Gene conversion is one mechanism to account for increased
SMN2 copy number in the absence of SMN1 in SMA (Burghes,
1997). In this scenario, the SMN1 gene actually contains part of
SMN2, in particular within exon 7 (Wirth et al., 1995; Devriendt
et al., 1996; Hahnen et al., 1996; van der Steege et al., 1996;
Campbell et al., 1997; DiDonato et al., 1997b). It is hypothesized
that type I SMA patients have deletions of SMN1 on both
chromosomes. Type II SMA patients have an SMN1 deletion on
one chromosome and a SMN1-to-SMN2 conversion on the other
chromosome (three copies of SMN2). Type III SMA patients have
SMN1-to-SMN2 converted genes on both chromosomes (four
copies).
While the inverse relationship between SMN2 copy number
and disease severity generally holds true in SMA, there are some
exceptions. For example, there are cases of type II and III SMA
patients who harbor only two copies of SMN2 instead of the
predicted three or four copies (Prior et al., 2009; Bernal et al.,
2010; Vezain et al., 2010). Sequencing of SMN2 in these cases
revealed the presence of a rare single nucleotide variant (SMN2
c.859G>C) in exon 7 (Prior et al., 2009; Bernal et al., 2010; Vezain
et al., 2010). This variant regulates the splicing of SMN2 pre-
mRNAs so that a greater proportion of SMN2 transcripts contain
exon 7. This variant may either create an additional SF2/ASF
binding to promote exon 7 inclusion (Prior et al., 2009) or disrupt
a hnRNPA1-dependent splicing silencer element (Vezain et al.,
2010).
Intrafamilial variability in clinical presentation has been
reported in SMA families with more than one affected sibling
(Burghes et al., 1994; Cobben et al., 1995; Hahnen et al., 1995;
McAndrew et al., 1997; Cuscó et al., 2006). Even though the
siblings are haploidentical with respect to SMN2 copy number,
they have differing clinical presentations. This would suggest that
there are SMN2-independent modifiers of disease severity for
SMA. Plastin-3 (PLS3) mRNA levels were higher in females with
milder SMA than in discordant siblings with a more severe SMA
clinical presentation (Oprea et al., 2008; Stratigopoulos et al.,
2010; Bernal et al., 2011; Yanyan et al., 2014). In some families,
however, female siblings with a more severe SMA phenotype
show high PLS3 mRNA levels (Bernal et al., 2011). It is possible
that the modifier property of PLS3 is age- and sex-dependent
as well as incompletely penetrant; alternatively, PLS3 may not
actually be a major modifier of SMA phenotype. There may be
other non-SMN2molecular modifiers of disease severity in SMA.
It is important to identify and characterize these novel modifiers
for the development of novel SMA biomarkers and targets for the
development of therapeutic strategies for SMA as well as for the
planning of current and future clinical trials in SMA (Wirth et al.,
2013).
MEASURING SMN1 AND SMN2 CNVs
Because SMN2 copy number influences disease severity in
SMA, there is prognostic value in accurate measurement of
SMN2 copy number from patients being evaluated for SMA.
Molecular diagnosis of SMA— i.e., loss of SMN1—has historically
been made using a polymerase chain reaction (PCR)-based
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assay followed by digestion of the PCR product with specific
restriction endonucleases (PCR-RFLP; Lefebvre et al., 1995; van
der Steege et al., 1995). Numerous assays have since been
developed to quantify SMN2 copy number in DNA samples
from SMA patients. These assays include radioactive PCR
(Coovert et al., 1997; McAndrew et al., 1997), fluorescent
PCR (Taylor et al., 1998), quantitative (real-time) PCR (qPCR;
Feldkötter et al., 2002; Anhuf et al., 2003; Gómez-Curet et al.,
2007), competitive PCR/primer extension (Gérard et al., 2004),
denaturing high performance liquid chromatography (Su et al.,
2005), multiplex ligation-dependent probe amplification (MLPA;
Arkblad et al., 2006; Scarciolla et al., 2006; Huang et al., 2007;
Alías et al., 2011; Fang et al., 2015), quantitative capillary
electrophoresis fragment analysis (Kirwin et al., 2013), short-
amplicon melt profiling (Dobrowolski et al., 2012), fluorescent
multiplex PCR/capillary electrophoresis (Wang et al., 2010a,b),
and universal fluorescent triprobe ligation (Wang et al., 2014a).
An important limitation of these established PCR-based copy
number assays is the requirement for a parallel-run calibration
curve to assign a breakpoint necessary that identifies placement
of an ordinal SMN2 value. Additionally, these techniques cannot
easily distinguish unit differences in SMN1 or SMN2 when the
copy number is >3 (Gómez-Curet et al., 2007; Alías et al., 2011;
Prior et al., 2011).
To overcome some of the limitations associated with the PCR-
based assays described above, digital PCR (dPCR) distributed
across a large number of partitions by limited dilution so that
some partitions will lack the template DNA (Sykes et al., 1992;
Vogelstein and Kinzler, 1999). The absolute abundance of the
target gene can be measured by counting the number of positive
partitions and the number of negative partitions. dPCR can
reliably and accurately measure SMN1 and SMN2 copy numbers
over a wide range, i.e., between 0 and 6 copies (Zhong et al., 2011;
Stabley et al., 2015).
SMN1 AND SMN2 CNVs IN ALS
Amyotrophic lateral sclerosis (ALS) is amostly adult-onsetmotor
neuron disease characterized by a progressive loss of motor
function leading to paralysis and respiratory failure (Boylan,
2015; Statland et al., 2015). Unlike SMA, ALS is caused by
degeneration of LMNs as well as upper motor neurons (UMNs).
ALS is usually fatal within 3–5 years after disease onset but there
is considerable variability with respect to duration as well as
phenotypic presentation (Swinnen and Robberecht, 2014). Most
cases of ALS are sporadic in nature since there is no apparent
family history. Approximately 10% of ALS is considered familial
since either a causative gene has been identified or there is
strong family history. With the recent advents of whole exome
and whole genome sequencing, the genetic bases of almost 70%
of familial ALS and 10% of sporadic ALS have been identified
(Renton et al., 2014).
There are many case studies reporting the co-occurrence of
SMA and ALS within a family (Appelbaum et al., 1992; Camu
and Billiard, 1993; Orrell et al., 1997; Corcia et al., 2002a) which
suggests that SMN1 deficiency may lead to ALS in addition to
SMA. SMN1 deletions, however, have not been observed in either
familial or sporadic ALS patients (Orrell et al., 1997; Corcia et al.,
2002a). Furthermore, no intragenic point mutations in SMN1
have been reported in the ALS population (Blauw et al., 2012).
The intrafamilial coexistence of SMA and ALS, therefore, occurs
by chance.
Even though loss of SMN1 is not associated with ALS, CNVs
in the SMN genes may modulate the clinical severity of ALS in
addition to SMA. Multiple studies suggest that deletion of SMN2
leads to increased risk of the sporadic forms of amyotrophic
lateral sclerosis (ALS) (Veldink et al., 2001, 2005; Kim et al.,
2010; Corcia et al., 2012; Lee et al., 2012). Additionally, atypical
SMN1 copy number—in other words, any number other than
two—can affect the risk of ALS (Corcia et al., 2002b, 2006; Blauw
et al., 2012; Wang et al., 2014b). Other studies, however, have
shown no association between deletion of either SMN1 or SMN2
in ALS (Jackson et al., 1996; Moulard et al., 1998; Parboosingh
et al., 1999; Crawford and Skolasky, 2002; Gamez et al., 2002).
The discrepant results from these studies may be due, in part, to
different assays used to assess SMN1 and SMN2 CNVs as some
reports using quantitative PCRwhile others usedMLPA or RFLP.
SMN and some ALS-associated proteins are involved in
common biochemical pathways. Both familial and sporadic
ALS have been linked to mutations in fused in sarcoma (FUS)
(Kwiatkowski et al., 2009; Vance et al., 2009) (OMIM #608030) as
well as in TAR DNA binding protein-43 kDa (TDP-43) (Kabashi
et al., 2008; Sreedharan et al., 2008) (OMIM #612069). Both FUS
and TDP-43 colocalize with SMN in subnuclear gems and ALS-
associated mutations in FUS and TDP-43 reduce gem localization
of SMN (Shan et al., 2010; Yamazaki et al., 2012; Gerbino et al.,
2013; Groen et al., 2013; Ishihara et al., 2013; Sun et al., 2015).
Gem localization of SMN, however, is not altered in other forms
of sporadic ALS (Kariya et al., 2014). These mutant proteins also
disrupt the SMN-mediated assembly of the splicingmachinery by
disrupting the interaction between SMN and U1-snRNPs (small
nuclear ribonucleoprotein particles; Gerbino et al., 2013; Tsuiji
et al., 2013; Sun et al., 2015; Yu et al., 2015). Additionally, ALS-
associated FUS mutations disrupt the localization of SMN to
axons (Groen et al., 2013). The SMN function, therefore, may be
disrupted in certain forms of ALS.
Ectopic overexpression of SMN protects NSC34 motor
neuron-like cells from cell death induced by ALS-
associated mutant superoxide dismutase 1 (SOD1) (OMIM
#105400) (Zou et al., 2007). The SOD1(G93A) transgenic
mouse model for ALS that also harbors a knockout of
1 mSmn allele (SOD1(G93A)+/−;mSmn+/−) exhibits a
more severe ALS phenotype than SOD1(G93A) ALS mice
(SOD1(G93A)+/−;mSmn+/+) (Turner et al., 2009). Furthermore,
ectopic overexpression of SMN in neurons and glia improves
motor function of and delays motor neuron loss in SOD1(G93A)
ALS mice (Turner et al., 2014). Strong transgenic overexpression
of SMN2—in other words, eight copies of SMN2—delayed
disease onset in the SOD1(G86R) mouse model for ALS
(Kariya et al., 2012). Thesestudies suggest that increasing SMN
expression may modulate disease severity in ALS. It will be
interesting to determine the effect of SMN2 overexpression on
disease severity in FUS- and TDP-43-associated ALS.
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SMN1 AND SMN2 CNVs IN PMA
Progressive muscular atrophy (PMA) is an adult-onset motor
neuron disease characterized by loss of LMNs (Rowland, 2010;
Liewluck and Saperstein, 2015). It is a rare and sporadic
disorder that is clinically distinct from ALS even though
subclinical involvement of UMNs has been observed in many
PMA patients. Those PMA patients exhibiting a more severe
clinical presentation tend to harbor higher SMN1 copy numbers
(Kuzma-Kozakiewicz et al., 2013). No relationship between
SMN2 copy number and disease severity was noted in these PMA
patients. Moulard et al. (1998) noted that the frequency of SMN2
deletion was higher in a small group of patients with sporadic
LMN disease.
CONCLUSIONS
CNVs in the SMN genes can modulate disease severity in SMA
as well as in other motor neurons. It is well-established that
SMN2 copy number is inversely correlated with disease severity
in SMA. Because of this relationship, SMN2 is a primary target for
the development of therapeutics for SMA (Arnold and Burghes,
2013; Cherry et al., 2014). Numerous approaches including
promoter activation, increased inclusion of exon 7 and protein
stabilization are currently being developed to increase SMN2
expression. With respect to other motor neuron diseases, it is
presently unclear whether increasing SMN1 or SMN2 expression
would be beneficial or detrimental. On one hand, increasing
SMN expression provides neuroprotective benefit to cell culture
and transgenic mouse models for ALS; however, some genetic
studies suggest that duplication of SMN1 increases the risk of
sporadic ALS. Future studies will assess the relationship between
SMN1 and SMN2 CNVs and disease risk and progression in
ALS and PMA as well as in other disorders affecting motor
neurons.
SMN2 copy number is becoming an inclusion criterion for
many clinical trials for SMA. Additionally, SMN2 copy number
can be used to help guide the type of care SMA patients
will receive. It is, therefore, essential to be able to accurately
and reliably measure SMN2 CNVs in SMA patient samples,
especially for those individuals harboring more than three copies
of SMN2. Newly developed technologies like dPCR offer a means
to accurately determine SMN2 copy number over a wider range.
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